EQS-News: Gerresheimer AG: Annual General Meeting backs growth course

Gerresheimer AG: Annual General Meeting backs growth course

• Dividend of EUR 1.25 per share after strong financial year 2022
• High approval rates for all agenda items
• Forecast reaffirmed: double-digit growth in revenues and earnings

Duesseldorf, June 7, 2023. The Annual General Meeting of Gerresheimer AG has expressed its confidence in the Management Board and Supervisory Board with regard to the growth course embarked on by the company, recording high approval rates for all agenda items. The company is paying its shareholders a dividend of EUR 1.25 for the past financial year 2022. At the same time, the Annual General Meeting approved the creation of new authorized and conditional capital, giving Gerresheimer the option to be flexible when financing its planned further growth. CEO Dietmar Siemssen reaffirmed the company’s forecast, with revenues and adjusted EBITDA expected to grow organically by at least 10 %.

“Today, Gerresheimer is a profitable growth company — and I believe that our best years lie ahead of us,” said Dietmar Siemssen, CEO of Gerresheimer AG: “As a provider of systems and solutions, we are a key strategic partner of the pharma and biotech industries and are growing in all areas. In particular, medical devices for biopharmaceuticals, including the new GLP-1 applications, are currently offering us excellent growth opportunities.” The company is also aiming for double-digit growth rates in revenues and adjusted EBITDA in the coming years.

Dividend of EUR 1.25 for strong financial year 2022

The Annual General Meeting approved a dividend of EUR 1.25 per share for the financial year 2022. This corresponds to a payout ratio of around 27 % of adjusted net income, which is once again at the upper end of the 20 % to 30 % range defined by Gerresheimer. The dividend is to be paid out on June 12, 2023.

In the financial year 2022, Gerresheimer recorded a strong performance in a challenging economic environment, generating revenues of EUR 1.82 billion and adjusted EBITDA of EUR 354 million.

High approval rates

With 81.27% of the share capital present, the Annual General Meeting adopted all resolutions by a large majority. As a result, the actions of the Management Board and Supervisory Board were approved by a large majority. Deloitte GmbH Wirtschaftsprüfungsgesellschaft, Duesseldorf, was elected as auditor for the financial year 2023.

The detailed voting results for the items on the Annual General Meeting’s agenda are available at: 
https://www.gerresheimer.com/en/company/investor-relations/annual-general-meeting 

The speech by the Chief Executive Officer at the Annual General Meeting is available at: https://www.gerresheimer.com/en/company/investor-relations/annual-general-meeting 

The Annual Report is available at: 
https://www.gerresheimer.com/en/company/investor-relations/reports 

Contact at Gerresheimer AG 
Press 
Jutta Lorberg
Head of Corporate Communication
T +49 152 900 345 46
[email protected]

Investor Relations 
Christian Lösse 
Senior Manager Investor Relations 
T +49 211 6181-314 
[email protected]

About Gerresheimer
Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 11,000 employees and generated annual revenues in 2022 of EUR 1.82bn. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.
www.gerresheimer.com